| Literature DB >> 33240285 |
Xianghui Kong1,2, Weiwen Duan2, Dingjin Li2, Xiaoxian Tang2, Zhenhua Duan2.
Abstract
Recently, the immuno-enhancing potential of polysaccharide from Auricularia auricula (AAP) has been an area of research interest. However, the immune-stimulatory activity and mechanisms of AAP in immunosuppressive mice treated with cyclophosphamide (CTX) are still poorly understood. This study aimed to evaluate the immuno-enhancing effects of AAP and mine its possible mechanisms. Firstly, polysaccharides were isolated from A. auricula and purified. Secondly, the immune-stimulatory activities of the first AAP fraction (AAP1) were evaluated in the CTX-treated mice. Results showed that AAP1 significantly enhanced immune organ indexes, remarkably stimulated IFN-γ, IL-2, IL-4, IL-10, and TNF-α levels in the serum, and dramatically up-regulated the mRNA levels of Claudin-1, Occludin and ZO-1. Compared to the CTX group, AAP1 administration restored the gut microbiota composition similar to that of the control group by decreasing the ratio of Firmicutes/Bacteroidetes and increasing the relative abundances of short-chain fatty acid-producing microbiota. This study provides useful information for its further application as an immune-stimulator in foods and drugs.Entities:
Keywords: Auricularia auricula; gut microbiota; immune-stimulatory activity; polysaccharides; short-chain fatty acid
Mesh:
Substances:
Year: 2020 PMID: 33240285 PMCID: PMC7681245 DOI: 10.3389/fimmu.2020.595700
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Figure 1Elution profiles of the polysaccharides isolated from Auricularia auricular: (A) Elution profile of the A. auricula polysaccharides (AAP) on DEAE-52 column; and (B) Elution profile of AAP1 on Sephacryl S-400 column.
Figure 2Fourier-transform infrared (FT-IR) spectra of AAP1 in the range of 400–4000 cm-1.
Effect of AAP1 treatment on immune organ indexes.
| Group | Thymus index (mg/g) | Spleen index (mg/g) |
|---|---|---|
| Control | 0.95 ± 0.11* | 5.47 ± 0.56* |
| CTX | 0.71 ± 0.05 | 4.18 ± 0.33 |
| AAP1 | 0.91 ± 0.61* | 5.02 ± 0.24* |
All data are expressed as mean ± SD. *p < 0.05: significantly different compared with the cyclophosphamide (CTX) group.
Figure 3Effects of AAP1 on cytokine release in serum of cyclophosphamide (CTX)-treated mice. (A) interferon-γ (IFN-γ); (B) interleukin-2 (IL-2); (C) IL-4; (D) IL-10; and (E) tumor necrosis factor-α (TNF-α). All data are expressed as mean ± SD. *p < 0.05 and **p < 0.01: significantly different compared with the CTX group.
Figure 4Effects of AAP1 on tight junction protein expression of colonic tissues of CTX-treated mice. (A) ZO-1, (B) Occludin, and (C) Claudin-1. All data are expressed as mean ± SD. *p < 0.05 and **p < 0.01: significantly different compared with the cyclophosphamide (CTX) group.
Figure 5Effects of AAP1 on the gut microbiota at the level of phylum (A) and genus (B).
Figure 6LEfSe analyses of gut microbiota regulation and immune response phylotypes. Phylotypes less than LDA 2 score are not reported.
Figure 7Determination of short-chain fatty acids (SCFAs) in cecal contents. (A) acetate; (B) propionate; and (C) butyrate. All data are expressed as mean ± SD. *p < 0.05 and **p < 0.01: significantly different compared with the cyclophosphamide (CTX) group.